Orforglipron vs semaglutide
Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist peptide given as a weekly injection or a daily tablet. This page brings together our reports on each, and on studies that looked at both.
What our reports show
No report we hold compared orforglipron with semaglutide directly. The one report that mentions both, an EMA committee news item, is a regulatory update. It describes orforglipron as an alternative to injectable and other oral GLP-1 receptor agonists. It reports no trial data, and the European Commission decision is pending.
The orforglipron evidence we hold is against placebo or a different drug class. In ATTAIN-J, the mean bodyweight change at week 72 in Japanese adults was -5.9% (6 mg), -8.7% (12 mg) and -7.9% (36 mg), against -0.6% with placebo. In ACHIEVE-2, a sponsor registry entry, HbA1c at week 40 fell by 1.32, 1.74 and 1.73 with three orforglipron doses and by 0.76 with dapagliflozin 10 mg. No formal test result is posted.
The semaglutide reports also come from separate populations. A FLOW post hoc analysis of 3533 adults with CKD and type 2 diabetes found HbA1c differences versus placebo of -0.7% to -1.0% with semaglutide 1.0 mg at Week 104. A registry entry in obesity-related HFpEF with type 2 diabetes reported weight change of -10.2% with semaglutide 2.4 mg and -3.2% with placebo at week 52.
These figures should not be set side by side. The patients differ (Japanese adults with obesity, people on metformin, CKD, HFpEF). So do the comparators, doses, durations (72, 40, 104 and 52 weeks) and endpoints. Two of the four trial reports are registry entries, not peer-reviewed papers. Until a head-to-head trial is reported, these reports cannot show which drug works better or is better tolerated.
Written only from the reports below and checked against them. Updated 13 November 2026.
Studies that looked at both
- EMA committee backs orforglipron (Foundayo) for weight management and type 2 diabetesRegulatory · 18 October 2026
Orforglipron
- Orforglipron lowered apnoea-hypopnoea index in two 52-week phase 3 OSA trialsRandomised trial · 10 November 2026
- Oral orforglipron reduced bodyweight more than placebo at 72 weeks in Japanese adultsRandomised trial · 1 November 2026
- Oral orforglipron vs dapagliflozin on metformin: ACHIEVE-2 HbA1c results postedTrial registry · 18 October 2026
- Orforglipron with insulin glargine: larger HbA1c fall than placebo in phase 3Randomised trial · 11 October 2026
Semaglutide
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
- Semaglutide and HbA1c, weight and BP across CKD stages in FLOW post hoc analysisRandomised trial · 5 November 2026
- Semaglutide 2.4 mg in obesity-related HFpEF with type 2 diabetes: phase 3 registry resultsTrial registry · 3 November 2026
- Triple agonist UBT251 lowers HbA1c in Chinese adults with type 2 diabetes in phase 2 trialRandomised trial · 28 October 2026
- CagriSema in type 2 diabetes: meta-analysis of six trials shows HbA1c and weight fallsMeta-analysis · 28 October 2026
- CDSCO expert committee: trial permission recommended for oral semaglutide, 3 moreRegulatory · 24 October 2026
- Semaglutide safety by eGFR in FLOW: fewer serious adverse events than placeboRandomised trial · 22 October 2026
- CDSCO expert committee: no Phase III waiver for Alkem semaglutideRegulatory · 15 October 2026
- Semaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trialRandomised trial · 10 October 2026
- Chemically synthesised semaglutide HD1916 met equivalence with Wegovy for weight loss in Chinese adultsRandomised trial · 10 October 2026
For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 13 November 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.